Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113918 | 0.83 | HCAR2 (0.45) | HCAR3HCAR2CYP1A2 | |
| SCHEMBL15478105 | 0.83 | ALDH1A1 (0.38) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL2258560 | 0.81 | ALDH1A1 (0.38) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL31263237 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL6814719 | 0.70 | KMT2A (0.37) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL12519883 | 0.67 | LMNA (0.37) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL7529634 | 0.65 | MEN1 (0.34) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL12445270 | 0.65 | ALDH1A1 (0.32) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL7529638 | 0.65 | ALDH1A1 (0.33) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL5880765 | 0.60 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8481574-B2 | (2Z)-2-(3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene)-1-(5-chloro-2-methoxyphenyl)ethanone; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2013-07-09 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985768-B2 | 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130953-A2 | 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080255123-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008063781-A2 | CHEMICAL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008028094-A1 | COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
| US-5300672-A | For water systems, plant diseases | ROHM AND HAAS COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| US-5166390-A | Bactericides | ROHM AND HAAS COMPANY (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | ALDH1A1 1737/4885MAPT 3161/4885KDM4E 2641/4885 |
| US-20080255123-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | ALDH1A1 1179/4885MAPT 1588/4885KDM4E 1754/4885 |
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | ALDH1A1 1497/4885MAPT 1751/4885KDM4E 1554/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | ALDH1A1 1465/4885MAPT 2290/4885KDM4E 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.